Electromed, Inc. Hits New 52-Week High of $39.70, Up 445.88%

Electromed, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 39.70 on May 29, 2026. This achievement marks a remarkable 445.88% increase in the stock's performance over the past year, significantly outpacing the S&P 500's growth of 28.21% during the same period. With a market capitalization of USD 197 million, Electromed operates within a competitive industry landscape. The company maintains a price-to-earnings (P/E) ratio of 22.00, reflecting its valuation relative to earnings. Additionally, Electromed's return on equity stands at an impressive 20.11%, indicating effective management of shareholder equity. The stock's price-to-book ratio is recorded at 4.33, suggesting a premium valuation compared to its book value. Despite a dividend yield of 0.00% and a debt-to-equity ratio of -0.30, Electromed's recent performance underscores its strong position in the market. The stock's previous 52-week low was USD 17.73, highlighting the significant upward trajectory it has experienced.